Antibody Shows Positive Results in Hep C Trial
REHOVOT, Israel-Officials from XTL Biopharmaceuticals are reporting positive results of the first monoclonal antibody to treat hepatitis C (HCV).
XTL-002, the company's monoclonal antibody, has been tested in Phase 1a studies and has reportedly reduced HCV and RNA levels in more than half the patients treated with one dose.
There were no serious adverse effects reported of the intravenous infusions. XTL-002 is a human high-affinity monoclonal antibody.
Hepatitis C is a viral bloodborne disease that attacks the liver and can cause jaundice, fatigue, pain, and vomiting. It can lead to liver damage and cancer. There are an estimated 4 million Americans who have the virus.
XLT Biopharmaceuticals is working on a group of therapies designed to fight a variety of chronic viral infections, drug-resistant bacteria, and systemic fungal infections.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
